Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of “Hold” from Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned an average recommendation of “Hold” from the nineteen ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $123.1667.

A number of analysts have recently commented on the company. Guggenheim cut their price target on Illumina from $122.00 to $114.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Stephens set a $110.00 price target on Illumina and gave the company an “overweight” rating in a research note on Monday, August 4th. Canaccord Genuity Group lifted their price target on Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Scotiabank lowered Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target on the stock. in a research note on Friday, July 11th.

Illumina Stock Performance

Illumina stock opened at $99.96 on Tuesday. The business’s 50-day moving average price is $99.29 and its two-hundred day moving average price is $88.46. Illumina has a 12-month low of $68.70 and a 12-month high of $156.66. The stock has a market cap of $15.36 billion, a PE ratio of 12.65, a P/E/G ratio of 2.25 and a beta of 1.43. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the firm posted $0.36 earnings per share. The business’s revenue for the quarter was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, analysts expect that Illumina will post 4.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in ILMN. Rise Advisors LLC lifted its stake in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares during the period. Rakuten Securities Inc. lifted its stake in shares of Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 270 shares during the period. Center for Financial Planning Inc. acquired a new position in shares of Illumina in the first quarter worth approximately $33,000. Finally, Fourth Dimension Wealth LLC acquired a new position in shares of Illumina in the fourth quarter worth approximately $40,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.